Selected article for: "acute sars cov respiratory syndrome coronavirus and lymphoblastic leukemia"

Author: Ragoonanan, Dristhi; Khazal, Sajad J.; Mejia, Rodrigo; Ewing, Linette; Durand, Jean-Bernard; Bashoura, Lara; Tayar, Jean; Dailey Garnes, Natalie; Petropoulos, Demetrios; Tewari, Priti; Bhatti, Micah; Ahmad, Ali Haider; Cortes, Jose; Razvi, Shehla; McBeth, Katrina; Swinford, Rita; Shoberu, Basirat; Waseemuddin, Waseem; Chi, Linda; Gill, Jonathan B.; Zaky, Wafik; Daw, Najat; Gutierrez, Cristina; Tereffe, Welela; Kebriaei, Partow; Rezvani, Katayoun; Shpall, Elizabeth J.; Champlin, Richard E.; Mahadeo, Kris M.
Title: Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2
  • Cord-id: 6boex39m
  • Document date: 2021_2_4
  • ID: 6boex39m
    Snippet: Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/clinical sequelae. We describe 2 diagnostically challenging cases of SARS-CoV-2 and Multi-Inflammatory Syndrome-Adult (MIS-A), in patients with a history of acute lymphoblastic leukemia following cellular therapy administ
    Document: Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/clinical sequelae. We describe 2 diagnostically challenging cases of SARS-CoV-2 and Multi-Inflammatory Syndrome-Adult (MIS-A), in patients with a history of acute lymphoblastic leukemia following cellular therapy administration and review evolving characterization of both the natural course of SARS-CoV-2 infection and toxicities experienced in younger cancer immunotherapy patients. Vigilant monitoring for unique presentations and epidemiologic surveillance to promptly detect changes in incidence of either condition may be warranted.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute kidney injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acute lymphoblastic leukemia: 1, 2
    • abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • abdominal pain and low grade fever: 1, 2, 3, 4
    • abdominal pain and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • abdominal pain and lung biopsy: 1
    • abdominal pain and lung opacity: 1, 2
    • abdominal pain and lymphoblastic leukemia: 1, 2
    • acute kidney injury and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute kidney injury and lung biopsy: 1, 2
    • acute kidney injury and lymphoblastic leukemia: 1, 2
    • acute lymphoblastic leukemia and low molecular weight heparin: 1
    • acute lymphoblastic leukemia and lymphoblastic leukemia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute phase and low molecular weight heparin: 1, 2, 3, 4, 5, 6
    • acute phase and lung biopsy: 1, 2, 3, 4
    • low molecular weight heparin and lymphoblastic leukemia: 1